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ABSTRACT 
Background:  New generation Direct-acting antivirals (DAAs) for the treatment of chronic 
hepatitis C infection have been on the market for more than 3 years since late 2013. Whether 
these medications cure patients at the rates claimed in clinical trials is not clear. Furthermore, as 
compliance is known to affect treatment outcomes, DAAs compliance rate is worth studying.  
Methods: We analyzed the association of social-demographic, DAA use, enrollment with 
Kentucky Medicaid Managed Care Organizations (MCOs) and comorbidities, and DAA 
compliance in 1128 Kentucky Medicaid members treated with DAAs between August 07, 2014 
and August 06, 2016. 
Results: Age, MCOs, liver fibrosis or cirrhosis, the use of ribavirin as supportive treatment of 
DAAs and taking more than one DAA were significant determinants of patient compliance. Age 
above 60 and being enrolled with Wellcare were associated with an increase in hepatitis C 
medications adherence after adjusting for all other risk factors (1.434 [1.045, 1.968] for 
age >=60 in comparison to age between 50-59, 0.58 [95% CI: (0.37, 0.89)], 0.35 [95% CI: (0.21, 
0.58)], 0.64 [95% CI: (0.42, 0.99)] and 0.55 [95% CI: (0.40, 0.76)] respectively for Aetna, 
Anthem, Humana and Passport compared with Wellcare). In contrast, being comorbid with liver 
fibrosis/cirrhosis, taking ribavirin or more than one DAA were significantly related to decreased 
adherence (0.74 [0.57, 0.96], 61.6% [0.26, 0.58], 0.50 [0.29, 0.86 respectively].  Use of Sovaldi 
and being comorbid with rheumatoid arthritis also had an impact without achieving significance. 
Conclusion: The findings of this study can be a useful screening tool for patients with factors that 
have predispositions for noncompliance. However, more studies in this area should be done to 
endorse these findings before they can be translated into clinical practice.   
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INTRODUCTION 
It is estimated that 3.5 million persons are living with hepatitis C virus (HCV) infection 
in the United States (Edlin et al, 2015). The state of Kentucky saw the highest incidence (4 per 
100,000 population) of acute hepatitis C infection in US from 2010 through 2014 (Center for 
Disease Control, 2014). During this time, Women of childbearing age between 15-44 who tested 
positive for HCV increased by 22% nationally and greater than 200% for Kentucky (Koneru et 
al, 2016). Among those acutely infected, chronic HCV (CHC) infection develops in 50-85% of 
the patients, posing great challenge and pressure to the medical and public health community 
(Lauer et al, 2001).  
Before the development of oral, direct-acting antivirals (DAAs), the backbone of chronic 
hepatitis C infection was the combination of pegylated interferon and ribavirin, which can 
eradicate the virus in more than 50% of patients (Poynard et al, 2003). Interferon induces host 
antiviral gene expression to inhibit virus replication, protein synthesis and assembly, along with 
enhancing immune response (Feld & Hoofnagle, 2003). As a guanosine analogue, ribavirin 
directly inhibits HCV replication and was found to potentiate the antiviral activity of interferon 
(Feld & Hoofnagle, 2003). They affect non-specific intracellular singling pathways of HCV 
replication. HCV treatment took a major step forward at the end of 2013 with the approvals of 
the second-generation protease inhibitor simeprevir (Olysio) and the nucleotide polymerase 
inhibitor sofosbuvir (Sovaldi). Both are DAAs and target only specific molecules and enzymes 
involved in various stages of the HCV life cycle. Ever since then, concerns have been raised by 
the states about the budgetary impact on Medicaid programs and beneficiary access to needed 
care (CMS, 2015). As much as the Center for Medicare and Medicaid Services (CMS) is trying 
to remain committed to Medicaid beneficiaries continuing to have access to needed prescribed 
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medications, they also recognize the challenges that have risen with DAA HCV drugs (CMS, 
2015). Limitations on treatment capacity makes it difficult to eliminate the hepatitis C virus in 
the United States (Brawley et al, 2016). Currently, less than 3 percent of the state's Medicaid 
beneficiaries with the disease receive treatment (Patrick 2016). For Harvoni alone, Medicaid 
spending nationwide on this medication soared 22-fold in one year, from just 95 million in 2014 
to $2.2 billion in year 2015 (5CMS 2016). In Kentucky, spending on Harvoni and Sovaldi in the 
first two quarters of fiscal year 2016 exceeded $25 million (Medicaid.org, 2017).  
For over a decade, the standard-of-care treatment for CHC has been interferon/ribavirin 
combination therapy, which has a 40-50% response rate in genotype 1 CHC patients and a 
response of up to 70-80% in genotype 2/3 CHC patients (Umar et al, 2013). With CHC infection 
cure rates between 90%-100% using the new generation oral medications in just 12 weeks’ time 
(US FDA, 2016), non-adherence is the most important risk factor for hepatitis C virus treatment 
failure (Sarpel et al, 2016; American Association for the Study of Liver Diseases, 2017). 
Although extensive studies have related poor adherence and outcomes with interferon and 
ribavirin-based therapy (Davis et al, 2003; McHutchison et al, 2002; Younossi et al, 2015), few 
studies, however, have evaluated the compliance rate of these highly effective direct-acting 
antivirals (DAAs) since their approval in late 2013 in non-controlled environments. A review 
published in 2014 analyzed the factors that modulate patient-driven adherence to the treatment of 
HCV infection with first generation protease inhibitors telaprevir (TVR) and boceprevir (BOC). 
It suggested that treatment complexity and side effects were key points for the adherence and 
success of the therapy (Larrey et al, 2014). A multicenter multinational phase 3 clinical trial 
discovered that a high overall adherence rate of 96.2% was achieved in 1483 patients treated 
with interferon- and ribavirin-free sofosbuvir (SOF) and ledipasvir (LED) in a fixed dose 
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combination therapy (Younossi et al 2016).  Up to now, the magnitude of the association of non-
compliance with treatment failure in patients with CHC infection is unclear, but any factors that 
may potentially reduce sustained virologic response can impede the hard-earned progress the 
Center for Medicare and Medicaid Services and state Medicaid agencies have made expanding 
access to this expensive cure regimen (Center for Disease Control (CDC), 2012; CMS, 2016; 
Gensen et al, 2014).  
We performed a case control study in CHC patients enrolled in Kentucky Medicaid 
population to evaluate the compliance to new DAAs and the factors associated with high 
compliance.  Subgroup analysis was also conducted to evaluate laboratory features and patient 
characteristics associated with treatment failure. This study aimed to bridge the gap in current 
hepatitis C treatment by exploring the compliance pattern in a state severely impacted by the 
hepatitis C epidemic.  
METHODS 
	
Dataset 
	
This retrospective observational study was carried out on hepatitis C patients enrolled 
with Kentucky Medicaid who were treated with the new generation antiviral therapies in 114 
counties in Kentucky between August 07, 2014 and August 06, 2016. Outpatient prescriptions 
covered through Kentucky Medicaid were managed either with Kentucky Medicaid’s Fee for 
Service (FFS) program through Magellan Health, a Pharmacy Benefit Manager, or carved out to 
the Medicaid Managed Care Organizations (MCOs), including Aetna Better Health (Aetna), 
Anthem Blue Cross Blue Shield (Anthem), Humana CareSource (Humana), Passport Health Plan 
(Passport) and Wellcare of Kentucky (Wellcare).  All 1128 patients were identified from the 
Kentucky Medicaid Database by searching 11 DAA medications approved by the Food and Drug 
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Administration (FDA) for use in CHC treatment: Daklinza (Daclatasvir), Epclusa 
(Sofosbuvir/Velpatasvir), Harvoni (Ledipasvir/Sofosbuvir), Inciviek (Telaprevir), Olysio 
(Simeprevir), Sovaldi (sofosbuvir), Technivie (Paritaprevir/Ombitasvir/Ritonavir), Viekira Pak 
(Dasabuvir/Paritaprevir/Ombitasvir/Ritonavir) and Zepatier (Elbasvir/Grazoprevir). All 5613 
hepatitis C related prescriptions including add-on ribavirin and interferon alpha prescriptions 
were examined.  
Compliance in our study was defined by the formulary metric Proportion of Days 
Covered (PDC). Reported as a percentage, it measured the number of days covered by 
prescriptions and divided by the number of days in the measurement period for that medication. 
It is usually preferred over the use of the Medication Possession Ratio (MPR) for a more 
conservative estimate of adherence (Nau, 2012). The PDC value for each member was the 
average PDC value of all hepatitis C medications reimbursed through Kentucky Medicaid during 
the study period. A patient was defined as “compliant” with hepatitis C treatment when the 
average PDC for all medications was 100%. 
The covariates obtained through each prescription entry included age (year), sex, race, 
county of residence, MCO/PBM, medication, medication National Drug Code (NDC), dispensed 
quantity, days of supply (days) and comorbidities. The corresponding comorbidities associated 
with each member on DAA were extracted as well for risk stratification. Age was categorized 
into 4 groups: ≤40, 40~49, 50~59 and ≥60. To better investigate the relationship of geographic 
location and compliance, counties were rearranged into new categories based on county Beale 
Code Urban-Rural Classification Scheme and Rural-Urban Continuum Codes (National Cancer 
Institute (NCI), n.d.). They are relabeled as “Metro county” if Beale Codes are between 1~3, 
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“Urban county” if between 4-6 and “Rural county” if between 7-9. Metro status is “1” if counties 
are grouped as “Metro county” and “0” if otherwise.  
All antiviral medications for hepatitis C were evaluated to investigate patient-specific 
adherence. Antiviral regimen may change, therefore an additional variable called “multiple 
treatment” was added to account for the variance in compliance, with a value of “1” if a member 
had received more than 1 DAAs in the designated time and “0” if otherwise. As patients can be 
on interferon alpha 2a and ribavirin for supportive therapy of DAAs, the use of either or both 
medications were added as covariates as well. 
A total of 31 types of comorbidities were captured by submission of out-patient 
prescription medication claims. included cancer, cardiovascular disease and respiratory disease 
among others. To make more general predictions on the impact of certain diseases on treatment 
compliance, two new composite comorbidity variables were created: “cardiovascular disease 
(CVD)” and “cancer”. The number and types of comorbidities related to members were 
compared in two groups: compliant members and non-compliant members.  
Statistical Analysis  
	
Statistical analysis was conducted with SAS 9.4 for Windows V6.1. Comparisons were 
performed using the Student t test, the Mann-Whitney-Wilcoxon test and Chi-square test in two 
compliance groups. To identify the factors shaping compliance with CHC treatment, bivariate 
relationships between compliance and the covariates described earlier were assessed. Covariates 
with a p-value of less than 0.05, together with covariates that have been identified to impact 
treatment adherence rate in previous studies, were selected into a backward stepwise multi-
variate logistic analysis.  
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Exploratory analyses included the use of descriptive statistics. Specifically, frequencies 
and percentages were examined for categorical variables-beale codes, DAAs, metro status, 
gender, race, MCOs and supportive therapy, and means, standard deviations and ranges were 
examined for continuous variables-age, PDC (%), number of comorbidities.  
The bivariate relationship between compliance and selected patient parameters were 
assessed to determine unadjusted associations. Rather than using age as an ordinal predictor, age 
categories are used as the predictor of interest to add clinical importance. The same applies for 
the variable “county”, as they are re-adapted based on Beale Codes and Metro Status.  
Multi-variate logistic regression was used for the final model, with the possibility of 
100% compliance with hepatitis C treatment as the outcome of interest. Backward elimination 
with a significance level of 0.1 was carried out for this model, starting with the main effects for 
all potential predictors mentioned in the Methods section.  
 
RESULTS 
	
	
A total of 1531 Medicaid members on hepatitis C treatment were identified between 
August 07, 2014 and August 06, 2016. Of these patients, 395 members were excluded from the 
study because they had a gap of 45 days or greater in coverage per year (n=302) (National 
Committee for Quality Assurance (NCQA), 2008), died (n=8), or were only on ribavirin, 
interferon alfa-2a or both (n=93), leaving 1128 active members enrolled contiguously using 
DAAs. 
The descriptive statistics for the members enrolled in this study are provided in Table 1. 
Of the 1128 patients, 682 (60.3) had a 100% compliance rate by PDC. Comorbidities were 
common with an average number of 6 for each member. The majority of patients were white 
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(41.4%) male (62.5%), came from metro areas (58.7%) and used passport (40.5%) as their PBM. 
They were mostly treated with Harvoni (58.6%) or Sovaldi (37.3%), together with ribavirin or 
ribavirin plus interferon for supportive care. 
Table 1. Summary of Descriptive Statistics for Medicaid Members Treated with DAAs between 
August 07, 2014 and August 06, 2016 
Variable Pertinent Statistics 
Age (years)  
n 1128 
Mean (SD) 52.4 (9.3) 
Median (Q1, Q3) 55 (47, 59) 
(Min, Max) (19, 71) 
PDC (%)  
n 1128 
Mean (SD) 95.7 (8.4) 
Median (Q1, Q3) 1 (94.4, 100) 
(Min, Max) (21.4, 100) 
Number of comorbidities (n)  
n 1128 
Mean (SD) 5.6 (2.8) 
Median (Q1, Q3) 5 (3, 7) 
(Min, Max) (0, 17) 
Beale code [n (%)]  
1 450 (39.9) 
2 131 (11.6) 
3 81 (7.2) 
4 35 (3.1) 
5 21 (1.9) 
6 116 (10.3) 
7 175 (15.5) 
8 38 (3.4) 
9 81 (7.2) 
Direct-acting Antivirals  
Daklinza 39 (3.5) 
Epclusa 11 (0.1) 
Harvoni 661 (58.6) 
Incivek 3 (0.0) 
Olysio 50 (4.4) 
Sovaldi 421 (37.3) 
Viekira Pak 35 (3.1) 
Zepatier 3 (0.0) 
Gender [n (%)]  
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Female 423 (37.5) 
Male 705 (62.5) 
Metro status [n (%)]  
0 466 (41.31) 
1 662 (58.7) 
Managed care organization [n (%)]  
Aetna 130 (11.5) 
Anthem 83 (7.4) 
Humana 141 (12.5) 
Magellan 12 (1.06) 
Passport 457 (40.5) 
Wellcare 305 (27.0) 
Race [n (%)]  
White 463 (41.0) 
Black 89 (7.9) 
Other races or ethnicity 278 (24.6) 
Not provided 198 (17.6) 
Supportive care  
Interferon 62 (5.5) 
Ribavirin 442 (39.2) 
Interferon or ribavirin 442 (39.2) 
 
 
Eight DAAs were used in the study population. Although all DAAs have similar safety 
and efficacy data in randomized controlled trials (Muir, 2014), compliance can be drastically 
lower than in a closely monitored environment, denoting potentially substantial deviance of 
outcome in actual clinical settings. The compliance statistics by DAA in Kentucky Medicaid 
population are illustrated in Figure 1. Epclusa and Zepatier were used in 11 and 3 patients 
respectively, but had the highest compliance rate at 90.9% and 100%. Both has similar dosing 
schedules and can be used with or without ribavirin and peginterferin, just like other DAAs used 
in this population. Thus, it is very likely that the high compliance presented in the population 
was due to coincidence. Harvoni and Sosaldi, both of which are mainstream treatments for 
chronic HCV infection, were the most heavily prescribed antivirals in Kentucky Medicaid 
beneficiaries. The percentage of patients with 100% compliance with Harvoni and Sovaldi 
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regimens ranges from 54%- 66%. The other DAAs were all less frequently used and poorly 
managed.  
 
Figure	1.	Percentage	Compliance	in	Kentucky	Medicaid	Population	by	DAA	
 
 
 
 It has been demonstrated in multiple studies that comorbidities have a major influence on 
the outcome of antiviral therapy of hepatitis C (El-Zayadi, 2009; Louie, 2012). They may exert 
effects through altering the course, on response of DAA, or on ribavirin/peginterferon treatment 
(EL-Zayadi, 2009). No statistical significance was established in the number of comorbidities, 
however, a trend towards a higher number of comorbidities among non-compliant group can be 
inferred from the pie charts below in Figure 2.  About 24% of members in the non-compliant 
group had less than 3 comorbidities vs. 27% of compliant group. At the other end of the 
spectrum are the extremely comorbid patients with 4-17 concurrent diseases. In the non-
51.28% 
90.91% 
65.20% 
33.33% 
50% 54.16% 
31.43% 
100% 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
Direct-acting	Antivirals
Percentage	of	100%	Adherence,	p<0.0001
Daklinza	n=39 Epclusa	n=11 Harvoni	n=661 Incivek	n=3
Olysio	n=50 Sovaldi	n=421 Viekira	Pak	n=35 Zepatier	n=3
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compliant group, 41% and 35% of the patients had 4-6 or greater than 7 comorbidities, 
respectively, in comparison with 40% and 33% in the compliant group.  
Figure	2.	Distribution	of	Comorbidities	in	Kentucky	Medicaid	Population	with	Hepatitis	C	
 
 
 
 
 
Bivariate comparisons of socio-demographic and other covariates are presented in Table 
2. Patients who were 100% compliant with hepatitis C therapy were compared to those who were 
5, 1% 
102,	23%
185, 41% 
154, 35% 
Non-compliant	Group
n=0 n=1-3 n=4-6 n>=7 
7, 1% 
179,	26%
272,	40%
224,	33%
Compliant	Group
n=0 n=1-3 n=4-6 n>=7 
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not; 682 of the 1128 patients (60.4%) were found to be compliant. This allows for the assessment 
of unadjusted associations of potential factors with compliance. Age (as a categorical variable), 
race, MCO, DAAs used in the therapy and whether patient got multiple DAA treatments were 
found to be significantly associated with medication compliance. Members in the less-than-49 
age group had a considerably lower compliance than those that were 50 and above. Most patients 
in the compliance group were white (42.1%) and resided metro areas (56.6%). Passport had the 
greatest number of patients in the compliance group while patients with Wellcare were better 
managed and more adherent (58.0% of Passport vs. 70.5% of Wellcare). To avoid uneven sample 
size in the DAA category where the majority (88.5%) of scripts were in only two drug categories 
(Faber & Fonseca, 2014), 8 DAA groups were downsized to 3: Harvoni, Sovaldi and other 
DAAs. As anticipated, patients on 1 DAA were 1.59 times more likely to adhere to therapy than 
those on 2 or more. The use of ribavirin for supportive care was also shown to have an impact, 
with non-compliance group having 15.3% more patients on ribavirin than compliance group. 
Table 2. Univariate Analysis of Hepatitis C Treatment Compliance 
 
Non-compliant 
Patients 
(n = 446) 
Compliant Patients 
(n=682) P value 
Age [n (%)]    
<40 47 (10.5) 80 (11.7) 
0.03 40-49 71 (15.9) 144 (21.1) 50-59 226 (50.7) 287 (42.1) 
>=60 102 (22.9) 171 (25.1) 
Male gender [n 
(%)] 275 (61.7) 430 (63.1) 0.64 
Race [n (%)]    
White 176 (39.5) 287 (42.1) 
0.003 Black 43 (9.6) 46 (6.7) Other 167 (37.4) 211 (30.9) 
Not Provided 60 (13.5) 138 (20.2) 
Beale code [n (%)]    
1-3 276 (61.2) 386 (56.6) 0.06 4-6 71 (15.9) 101 (14.8) 
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7-9 99 (22.2) 195 (28.6) 
Metro status [n 
(%)]    
0 170 (38.1) 296 (43.4) 0.08 1 276 (61.9) 386 (56.6) 
MCO [n (%)]    
Aetna 55 (12.3) 75 (11.0) 
0.0002 
Anthem 44 (9.9) 39 (5.7) 
Humana 57 (12.8) 84 (12.3) 
Magellan 8 (1.8) 4 (0.6) 
Passport 192 (43.1) 265 (38.9) 
Wellcare 90 (20.2) 215 (31.5) 
Comorbidities (n) 5.7 ± 2.9 5.5 ± 2.8 0.36 
Direct-acting 
Antivirals   
 
Harvoni 230 (46.6) 431 (59.1) 
0.0001 Sovaldi 193 (39.1) 228 (31.3) 
Other DAAs 71 (14.4) 70 (9.6) 
Multiple Treatment    
0 399 635 0.0303 1 47 47 
Supportive Care    
Ribavirin 216 (48.4) 226 (33.1) <.0001 
Interferon 27 (6.1) 35 (5.1) 0.5068 
Ribavirin or 
Interferon 216 (48.4) 226 (33.1) <.0001 
Data are expressed as frequencies (column percentage) of patients. 
The bivariate analysis between 31 comorbidities and compliance, arranged from the 
highest to the lowest frequency, is reported in Table 3. Patients with chronic kidney disease 
(CKD), depression and substance use disorder (SUD) were linked to the highest rate of 
compliance. This finding in patients with SUD is not unexpected, given that opioid treatment 
programs are structured to provide medical supervision over opioid detoxication and the 
administration of all other prescribed medications, including antivirals for hepatitis C (McCance-
Katz & Valdiserri, 2015). None of the disease states but liver fibrosis/cirrhosis was found to be 
statistically significant in relation to compliance. Although myocardial infarction, liver cancer, 
colorectal cancer, prostate cancer, osteoporosis and liver transplant were marginally significant 
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(p-value <=0.1), they were excluded from the final multi-variate logistic regression model 
because of their tendency to lead to inaccurate conclusions (King & Zeng, 2001). 
 
Table 3. Bivariate Associations Between Comorbidities with Hepatitis C Therapy Compliance 
Comorbidity Frequency Percentage compliant (%) 
Odds 
Ratio 
P 
value 
Cardiovascular disease 869 60.1 0.93 0.62 
Hypertension 800 60.1 0.95 0.72 
Hyperlipidemia 399 59.4 0.93 0.59 
Ischemic heart disease 171 57.9 0.88 0.46 
Heart failure 79 60.8 1.01 0.96 
Stroke/Transient heart attack 59 57.6 0.88 0.65 
Atrial fibrillation 28 53.6 0.75 0.45 
Myocardial infarction 26 42.3 0.47 0.06 
Substance use disorder 836 61.1 1.46 0.44 
Liver fibrosis/cirrhosis 637 57.3 0.74 0.01 
Rheumatoid arthritis 543 57.8 0.81 0.08 
Depression 511 61.3 1.06 0.62 
COPD/Bronchiectasis 480 61.0 1.04 0.73 
Asthma 374 60.7 1.01 0.91 
Anemia 274 57.7 0.86 0.28 
Chronic kidney disease 273 61.5 1.06 0.68 
Diabetes 268 60.1 0.98 0.88 
Hyperthyroidism 117 56.4 0.83 0.34 
Cataract 106 60.4 1.00 0.99 
Benign prostatic hyperplasia 80 58.8 0.93 0.75 
Cancer 72 51.4 0.67 0.10 
Liver cancer 41 46.3 0.55 0.06 
Breast cancer 9 44.4 0.52 0.32 
Colorectal cancer 9 88.9 5.28 0.08 
Lung cancer 9 55.6 0.82 0.76 
Prostate cancer 7 28.6 0.26 0.08 
Endometrial cancer 1 100.0 / 0.42 
Osteoporosis 46 73.9 1.90 0.06 
Glaucoma 41 70.7 1.61 0.17 
Liver transplant 22 40.9 0.45 0.06 
Alzheimer’s and related 
diseases 18 61.1 1.02 0.95 
Hip/Pelvic fracture 9 44.4 0.52 0.32 
Autism sectrum 1 0.0 / 0.22 
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Based on the result from the bivariate analysis in Table 2 and Table 3, the variables 
proposed for the multi-variate logistic regression model with backward elimination included age 
(as a categorical variable), race, MCO, DAAs, whether patient got multiple DAA treatments 
(multiple treatment) and use of ribavirin. To fully rule out the possibility of high-frequency 
comorbidities playing a role in compliance, the most common top 10 comorbidities were also 
incorporated into model: CVD, SUD, liver fibrosis/cirrhosis, rheumatoid arthritis, depression, 
COPD/Bronhiectasis, asthma, anemia, CKD and Diabetes. The statistics for factors that 
remained after backward elimination were recalculated in the final regression model. As a result, 
five variables were ultimately shown to be independently associated with compliance. These 
include group with age equal to or greater than 60 in comparison with those in 50-59, liver 
fibrosis/cirrhosis, Aetna, Anthem, Humana and Passport with Wellcare as the reference MCO 
group, Anthem with Humana as the reference group, the use of ribavirin and being treated with 
more than 1 DAAs. Having rheumatoid arthritis and taking Sovaldi both approach but fell short 
of significance (p=0.05). Adjusting for the other covariates, members with an age greater than 60 
were estimated to have 1.434 [95% CI: (1.045, 1.968)] times of the odds of achieving 
compliance than in those who were between age 50-59. Diagnosis of liver fibrosis or cirrhosis 
had 0.74 [95% CI: (0.57, 0.96)] times the odds of compliance of those who did not have this 
disease. Furthermore, lower odds of compliance were also found to be conditionally associated 
with the MCO affiliation. Specifically, the odds of compliance were estimated to be 0.58 [95% 
CI: (0.37, 0.89)], 0.35 [95% CI: (0.21, 0.58)], 0.64 [95% CI: (0.42, 0.99)] and 0.55 [95% CI: 
(0.40, 0.76)] respectively for patients managed by Aetna, Anthem, Humana and Passport, as 
compared with patients by Wellcare. Compared to those of Humana (0.55 [95% CI: (0.31, 
0.96)]), beneficiaries served by Anthem were about half as compliant, indicating that disparity of 
		
16	
drug utilization and adherence management were present in the Kentucky Medicaid managed 
care organizations.  Members who had had more than one DAAs in the two-year study period 
were estimated to have 0.50 [95% CI: (0.29, 0.86)] times of the odds of achieving compliance 
than in those who had one. Finally, the odds of being compliant is reduced significantly by 
61.6% [95% CI: (0.26, 0.58)] with ribavirin as supportive therapy than those only on DAAs.  
Table	4.	Patient	characteristics	independently	associated	with	hepatitis	C	therapy	compliance	
 Reference p-value Odds ratio 95% Confidence Interval 
Age >= 60 50 <= Age <= 59 0.0257 1.434 1.045– 1.968 
Liver Fibrosis/Cirrhosis No 0.0152 0.741 0.570 – 0.963 
MCO - Aetna Wellcare 0.0134 0.575 0.371 – 0.892 
MCO - Anthem Wellcare <.0001 0.351 0.211 – 0.584 
MCO - Humana Wellcare 0.0429 0.641 0.417 – 0.986 
MCO - Passport Wellcare 0.0003 0.554 0.403 – 0.761 
MCO - Anthem Humana 0.0356 0.547 0.311 – 0.960 
Multiple DAAs No 0.0128 0.502 0.291 – 0.864 
Rheumatoid Arthritis No 0.0706 0.789 0.610 – 1.020 
Ribavirin No <.0001 0.384 0.256 – 0.576 
Sovaldi No 0.0818 1.485 0.951 – 2.317 
 
DISCUSSION 
 
This is the first retrospective observational study that analyzes compliance influencing 
factors in HCV infected, state Medicaid patients taking new generation hepatitis C drugs. There 
are several factors that seem to influence adherence in this population. Older age above 60 has a 
positive impact on adherence, while “liver fibrosis/cirrhosis” was found to impair compliance 
considerably. Disease management between MCOs also differs significantly.  Gender, race, 
county of residency, number of comorbidities, comorbidities other than liver fibrosis or cirrhosis 
and whether patients received more than one DAA medication treatment were not shown to be 
relevant to compliance. 
Because of the recent introduction of DAAs up to today and the unique nature of the 
study population, our finding on DAA compliance can hardly be compared with research 
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findings in general HCV infected patients taking ribavirin and/or interferons, in terms of both 
overall adherence rate and contributing factors of compliance. A prospective cohort study in 
2010 in 1860 CHC patients initiating ribavirin and peginterferon revealed that only 38% of 
patients reported strict adherence to the regimen, defined as full-dose and persistent therapy as 
initially intended by physician (Marcellin, 2011). This stark comparison to 60.4% strict 
adherence rate with DAAs demonstrated the collaborative efforts from physicians, payers and 
patients to ensure treatment success. They found that HIV co-infection, no drug use during 
follow-up, genotype 3 and treatment naïve were independent predictors of adherence. A systemic 
review conducted in 2010 on factors influencing adherence in hepatitis-C infected patient 
concluded that factors, including psychiatric disorders, depression, higher ribavirin dose, 
negatively affected compliance and HIV co-coinfection and hemoglobin level seemed to play a 
positive role in promoting compliance (Mathes, Antoine, & Pieper, 2014). 
In our patient population, many of these factors were either near identical at baseline or 
unidentifiable in prescription claims. For example, Kentucky Medicaid’s FFS provider, 
Magellan, requires that patients with a history of psychosis, schizophrenia, bipolar disorder or 
schizoaffective disorder are ineligible for one of most commonly prescribed and evidence-
supported regimen in hepatitis C genotype 1 infection (Sovaldi, interferon alfa and weight-based 
ribavirin combination treatment), unless they are on therapy and compliant with this therapy as 
reflected by pharmacy paid claim histories (Fried et al, 2013).  
Many factors determine difference in compliance. These include internal factors, such as 
age, sex, race, hepatitis C genotype, comorbidities, all of which are impossible to change at the 
time of treatment. External factors, on the other hand, include all the environmental 
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circumstances that can be optimized throughout the treatment course. Treatment regimen, 
physicians and MCO enrollment are all examples of external factor.  
Age seems to be an irrelevant determinant of compliance in our study population until 
patients reach the age of 60, when it starts to show a marked positive effect.  This impact is not 
found in any previous studies done on hepatitis C patients using ribavirin and interferon. 
However, as counterintuitive as it may sound, increased likelihood of adherence with age has 
been demonstrated in multiple studies that investigated the determinants of adherence with 
antipsychotic medications (Gilmer et al, 2004) and rheumatoid arthritis (Viller et al, 1999).  The 
same result was also seen in Medicaid population with other medical concerns, such as 
hypertension (Monane et al, 1996; Bailey, Lee, Somes, & Graham, 1996), diabetes using 
sulfonylurea regimen (Sclar et al, 1999) and hyperlipidemia (Avon et al, 1998). Why older adults 
are more compliant is unknown, but it may be due to a slower paced life, better communication 
with health care professionals and decreased financial pressure. Avon specifically proposed that 
the number of prescribed medications, rather than old age per say, is the risk factor for 
noncompliance. This supports the connection of multiple DAA treatment with decrease 
compliance in our study.  
The study showed a link between both liver disease and rheumatoid arthritis and 
compliance. The lower compliance rate among patients with liver fibrosis or cirrhosis was well 
predicted in the clinical trials of DAAs. A systemic review of hepatitis C treatment published in 
2014 on Nature outlined the poor response rate of DAAs in patients with HCV genotype 2: 
patients with cirrhosis or fibrosis responded less well to Sovaldi + pegylated interferon + weight-
based ribavirin regimen (80% vs 92%) or Sovaldi + weight-based ribavirin alone therapy (54% 
vs 79%) (Kohli, Shaffer, Sherman, & Kottilil, 2014) than patients without it. The incomplete or 
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slow virologic response leads to a lack of motivation in physicians and patients, decreased 
adherence and early discontinuation of DAAs. In comparison, the link between rheumatoid 
arthritis and adherence is more straightforward. Rheumatoid arthritis is a chronic inflammatory 
disease affecting joints, causing stiffness, weakness, painful swelling and decreased range of 
motion (Arthritis Foundation, n.d.), thus directly hindering the medication taking behavior. 
The high cost of these medications helps classify hepatitis C antivirals as specialty 
medications. Regardless of whether a certain DAA is on the Medicaid Preferred Drug List (PDL) 
or not, it is required that physicians file prior authorization forms and ensure that diagnostic and 
therapeutic criteria are met before a DAA is approved for initiation of the first cycle (Aetna 
Better Health of Kentucky, 2017; Anthem Blue Cross Blue Shield, 2017; Humana CareSource, 
2017; Magellen Medicaid, 2017; Passport Health Plan, 2017; Wellcare of Kentucky, 2017). Once 
approved, the copay is comparable between DAAs and usually falls below $10 for a 28-day 
supply (Kentucky Cabinet for Health and Family Services (KCHFS), n.d.;). Instead, factors that 
tend to hinder treatment compliance in Medicaid population are typically adverse events or 
regimen complexity (in terms of dosing frequency and polypharmacy).  
Ribavirin is sometimes used as supportive care to increase rates of sustained virologic 
response (SVR) or to shorten treatment duration without altering the rates of SVR (Pawlotsky, 
2014). Pegylated interferon are also utilized in combination with DAAs to induce specific and 
nonspecific immune response against HCV and inhibit viral replication. They both have 
undesirable adverse effect, but ribavirin is more often associated with central nervous system, 
gastrointestinal, hematologic and dermatologic toxicities, such as headache, nausea, depression, 
hepatic toxicity, anemia, neutropenia, diarrhea and rash, thus leading to premature treatment 
discontinuation (Genetech, 2002).  
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Harvoni and Sovaldi have relatively high compliance rates among the eight DAAs used 
in this population. Both are dosed once daily, so the differences in compliance between the two 
usually lays in dosing complexity. Harvoni is commonly used as a single agent dosed daily in 
patients in chronic HCV infection without ribavirin, unless the patient is also a liver transplant 
recipient, while Sovaldi is often prescribed with ribavirin and interferon for genotype 1 infection 
(most of our population). However, after controlling for the use of ribavirin and interferon in the 
final model, Sovaldi was significantly more appealing to our patient population than other 
DAAs. The underlying mechanism for this huge variance is not clear. It can be due to the severe 
adverse events recently reported by the Institute for Safe Medication Practice. In the 12 months’ 
FDA Adverse Event Reporting System (FAERS) data between Novermber 2015 – October 2016, 
Harvoni was the primary suspect for 116 liver failures, 91 cases were correlated with Sovaldi and 
120 cases with Viekira pak (Quarter Watch, 2017). The exact association between adverse 
effects of DAAs and compliance should be further investigated in future studies. At the lowest 
compliance rate (31.4% and 33.3% respectively), Incivek and Viekira Pak each have a more 
frequent and complex dosing schedule. Incivek was discontinued in the US market for more than 
a year, but it was previously dosed at twice a day with or without ribavirin/peginterferon for 
chronic HCV infection other than genotype 1. Viekira Pak, on the other hand, is a copackaged 
product containing ombitasvir, paritaprevir and ritonavir as a fixed-dose combination tablet and 
dasabuvir as an individual tablet. Patients are supposed to take two combination tablets in the 
morning and one dasabuvir tablet twice daily.  
Even though patients with Wellcare were shown to be more compliant than all other 
MCOs contracted with Kentucky Medicaid, it is not well understood why this is the case. 
Kentucky Medicaid issues a “Guide to choosing a Medicaid Health Plan” to help (potential) 
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members choose among Magellan, Aetna, Anthem, Huamna, Passport and Wellcare every year 
based on individual needs. The latest issue for 2017 indicated that Wellcare exceled in “Getting 
child care quickly”, “21 and under dental visits”, “Getting adult care quickly” and “Adult overall 
satisfaction with health plan”. The connection between these performances and hepatitis C 
medication compliance management, however, is unknown. Wellcare, together with Coventry, 
Kentucky spirit, were the three health plans initially enrolling Medicaid beneficiaries when the 
implementation of Medicaid Managed Care was started in November 1, 2011. Additional 
managed care plans, Humana, Passport and Anthem, didn’t begin to provide services to the 
entire Medicaid population until July 1, 2017 (Marton et al, 2016). With Wellcare being more 
experienced with the Kentucky Medicaid population, they are better at therapy monitoring, 
building appropriate clinical criteria and efficient communication with physicians.  
The result of this study reflects the hepatitis C medication compliance in contiguously 
enrolled Kentucky Medicaid patients, but may not apply to overall Medical or general patients 
on DAAs. To remain consistent with national standard measurement for disease management 
(NCQA, 2008), 302 members were excluded from analysis due to excessive coverage gap. As a 
result, they either fall into an uninsured state of having incomes above Medicaid eligibility limits 
but below the lower limit for marketplace premium tax credits, or bumped to receive 
marketplace subsidies. Little data can be found on these people that fell into the gap in Kentucky, 
but it is clear that their quality of care can be severely compromised. In comparison to study 
population, this subgroup of Medicaid members is more likely to face challenges of higher co-
pay, less close treatment monitoring and experience more treatment interruptions and 
coordination for transition of care.  Chronic HCV patients of the same economic status outside 
Medicaid can be drastically distinctive as well. A study in 2010 that looked at the demographic 
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and health characteristics of the population who will be eligible for Medicaid under Affordable 
Care Act (ACA) found that both the nondisabled and the disabled adults who were currently 
enrolled in Medicaid were more likely to have poor general health, mental health and more 
chronic conditions on average relative to both uninsured and privately insured adults with 
incomes below 138% of the federal poverty level (FPL) (Holanhan, Kenney, & Palletier, 2010). 
They all imply that the resulted compliance in this study might be an optimistic estimation of 
DAA compliance in overall Medicaid patients and an underestimation of that in general 
population. 
There are several limitations in this study that are worth noting. Our data were derived 
from Kentucky Medicaid outpatient pharmacy claims. They provided very limited information 
on the severity of HCV infection, comorbidities (HIV or Hepatitis B coinfections), prior 
treatment history and social history. Although having these data could greatly add to the 
predictable accuracy of our study, it takes extensive time and manpower to manually go over all 
the prior authorization claims for all the DAAs and collect those data in a uniform format. On the 
other hand, public information on MCO’s prescription drug management, especially for specialty 
drugs, is nonexistent. Complete clinical criteria to get prior authorization approval are private 
information and not shared with the public. If the Kentucky Medicaid clinical criteria for all the 
MCOs and FFS could be accessed, we could determine the root cause for the difference in 
compliance.  
In conclusion, access to hepatitis C antivirals does not come easily. Aside from the 
financial shackles that all health insurance provider face, patients must meet as many as more 
than 20 clinical criteria to be eligible for DAA. Once access is granted, patients are entitled to 
therapy for once in their lifetime unless resistance or intolerance develops during the treatment 
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course. Therefore, it is not surprising to see payers closely monitor lab test and treatment course, 
require prior authorization every step of the way and approve therapies by cycle. If patients could 
be screened for characteristics that have been known to predispose them to noncompliance and 
manage them alongside hepatitis C, we could make a huge impact on hepatitis C treatment 
outcome. 
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